Advantage Alpha Capital Partners LP Has $311,000 Position in Xencor, Inc. (NASDAQ:XNCR)

Advantage Alpha Capital Partners LP lessened its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 45.5% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 13,548 shares of the biopharmaceutical company’s stock after selling 11,313 shares during the period. Advantage Alpha Capital Partners LP’s holdings in Xencor were worth $311,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in XNCR. GAMMA Investing LLC raised its position in shares of Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 508 shares during the last quarter. Quarry LP lifted its position in Xencor by 111.4% during the 3rd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 2,108 shares during the period. KBC Group NV lifted its position in Xencor by 26.0% during the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 813 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Xencor by 49.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 1,337 shares during the last quarter. Finally, Rockefeller Capital Management L.P. bought a new stake in shares of Xencor during the third quarter worth approximately $205,000.

Xencor Price Performance

NASDAQ XNCR opened at $12.95 on Tuesday. The firm’s 50 day moving average is $16.22 and its 200-day moving average is $20.30. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $912.48 million, a PE ratio of -4.05 and a beta of 0.74. Xencor, Inc. has a 12-month low of $12.54 and a 12-month high of $27.24.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. Equities research analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on XNCR. Piper Sandler raised Xencor from a “neutral” rating to an “overweight” rating and increased their target price for the company from $20.00 to $30.00 in a research note on Monday, December 2nd. Wells Fargo & Company dropped their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Finally, StockNews.com lowered Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $34.38.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.